Market research
CLSD Clearside Biomedical Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 60
- Dividend yield
- Not available
- Beta
- 1.79
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US1850631045
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 60
- Dividend yield
- Not available
- Beta
- 1.79
About
About Clearside Biomedical Inc
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. On November 23, 2025, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CLSD discussion.
5 years, 4 months ago
Clearside Biomedical, Inc is currently in a long term uptrend where the price is trading 100.6% above its 200 day moving average.
From a valuation standpoint, the stock is 98.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 14.8.
Clearside Biomedical, Inc's total revenue sank by 99.4% to $11K since the same quarter in the previous year.
Its net income has dropped by 129.7% to $-7M since the same quarter in the previous year.
Finally, its free cash flow fell by 366.6% to $-4M since the same quarter in the previous year.
Based on the above factors, Clearside Biomedical, Inc gets an overall score of 2/5.